Uncategorized Archives - Page 60 of 145

ThursdayJan 13, 2022 9:30 am

Long-Term Opioid Users at Risk of Depression, Study Finds

A new study has found that near-daily or everyday use of prescription opioids is linked to a higher risk of new onset depression, in comparison with occasional use of the drugs. While the number of new opioid prescriptions in the United States has dropped since 2012, the average duration of prescriptions and the proportion of 30-day opioid prescriptions increased between 2006 and 2017. The study was conducted by researchers at St. Louis University School of Medicine, led by Jeffrey Scherrer, the institution’s senior director of the Advanced Health Data Institute. Scherrer stated that the risk for new depression episodes in…

WednesdayJan 12, 2022 9:30 am

Researchers Explore How Pandemic Impacted Breast Cancer Screening in Low-Income Populations

After lung cancer, breast cancer is the deadliest type of cancer in the world, affecting women of all ages. Estimates show that about 13% of women develop the deadly cancer in their lifetime. In 2020, more than 2.2 million women were diagnosed with breast cancer, with some 680,000 succumbing to the ailment. These stats highlight the importance of early detection, which is mainly accomplished through breast cancer screening, in helping reduce mortality. Unfortunately, the onset of the coronavirus pandemic caused many postponements and cancellations in screenings not only for breast cancer but also other types of cancer. As a result,…

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

TuesdayJan 11, 2022 9:30 am

Study Finds Telehealth Improved Access to Perinatal Mental Healthcare During Pandemic

A new study has found that the use of telehealth for mental health services for infants and mothers in the course of the pandemic improved access to care. Perinatal anxiety and mood disorders occur after or during pregnancy. These disorders are associated with problems with an infant’s emotional and social development as well as poorer birth outcomes. Mothers with high psychosocial stress and low social support have a higher chance of developing perinatal disorders. The coronavirus pandemic disrupted social interactions and increased social isolation, which raised some concerns for the mental health of pregnant mothers. Limited in-person interactions became the…

MondayJan 10, 2022 1:24 pm

Deep Learning Model Could Accurately Classify Brain Tumors After One MRI Scan

Scientists from the School of Medicine at Washington University have created a deep-learning model that can classify brain tumors using an MRI scan. One of the researchers involved in the study, Satrajit Chakrabarty, stated that the research was the first to identify the absence or presence of a tumor from an MRI scan and directly determine the tumor class. The most common types of intracranial tumors include acoustic neuroma, pituitary adenoma, meningioma, brain metastases, low-grade glioma and high-grade glioma. Each tumor type was documented via histopathology, which involves the surgical removal of tissue from the site of a cancer and…

MondayJan 10, 2022 12:22 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology Mydecine’s primary focus is the…

MondayJan 10, 2022 10:27 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled "Psychedelics: More Than Just a Trip" during…

FridayJan 07, 2022 10:48 am

Review Finds Ketamine Effective in Treating Mental Health Disorders

Ketamine is a dissociative anesthetic that is used to induce loss of consciousness for medical procedures that don’t need muscle relaxation. Its effects include decreased sensation of pain and sedation. In addition to this, the drug possesses hallucinogenic properties that produce hallucinations similar to other drugs such as LSD. Research has shown that the use of low doses of ketamine in treating treatment-resistant depression is effective, with ongoing trials finding that the drug could also be used to effectively treat other psychiatric conditions. Recent research by Cambridge University Press explores how ketamine works in treating mental health conditions. For their…

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

ThursdayJan 06, 2022 2:29 pm

Timely Initiation of Treatment Improves Opioid Use Disorder Outcomes

Researchers at the University of Pennsylvania’s School of Medicine have discovered that a program which was designed to make buprenorphine administration timely and easy has increased the use of the treatment in hospital emergency departments significantly. Buprenorphine is a drug that’s used to stabilize opioid withdrawal and pacify cravings. The medication’s use can decrease overdose deaths and other complications associated with drug use while growing long-term engagement with care for opioid use disorder. The lead author of the study, Margaret Lowenstein, stated that the researchers utilized a behavioral design approach to make the execution of evidence-based treatment timely, attractive and…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Long-Term Opioid Users at Risk of Depression, Study Finds

Researchers Explore How Pandemic Impacted Breast Cancer Screening in Low-Income Populations

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Study Finds Telehealth Improved Access to Perinatal Mental Healthcare During Pandemic

Deep Learning Model Could Accurately Classify Brain Tumors After One MRI Scan

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

Review Finds Ketamine Effective in Treating Mental Health Disorders

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Timely Initiation of Treatment Improves Opioid Use Disorder Outcomes

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search